Luis M. Moura, MD, PhD, FESC, FASE, FACC

• Assistant Professor, Oporto University School
• of Medicine and Hospital Pedro Hispano
• Department of Medicine
• Medicine A
• Oporto, Portugal

Hemodialysis is associated with particular risk factors that are known to trigger dysrhythmias quit smoking 24 hours before surgery buy discount nicotinell 17.5 mg on-line, such as large changes in extravascular volume and rapid electrolyte shifts quit smoking meter generic 17.5mg nicotinell visa. Furthermore quit smoking support groups buy 52.5mg nicotinell mastercard, synthesis of matrix Gla protein (an important endogenous calcification inhibitor) is vitamin K dependent; thus quit smoking jacksonville florida discount 52.5 mg nicotinell, vitamin K antagonists may lead to excess vascular calcification quit smoking and constipation generic nicotinell 52.5 mg line. Since available treatments that reduce albumin leakage also exert other salutary effects on cardiovascular risk quit smoking nicotine withdrawal purchase nicotinell once a day, it is unlikely that the multiple benefits of these therapies could be disentangled. Despite differences in the populations studied and adjustment for confounding variables, the results are surprisingly consistent. A meta-analysis of 19 creatinine-based studies (including over 160,000 events) has shown that for each 20 mL/min/1. This meta-analysis included data from 1,234,182 participants in 21 cohorts from the general population. Indeed, trials of more-intensive versus less-intensive albuminuria reduction strategies (such as adding angiotensin-converting enzyme or direct renin inhibitors to angiotensin receptor blockers) have not shown additional cardiovascular protection (although their statistical power to do so was limited). As described in earlier chapters, the kidneys are responsible for a wide variety of physiologic processes including clearance of metabolic waste products, salt and water balance, blood pressure regulation, and hormone production. Even mild kidney disease has direct effects on the regulation of these processes and could therefore potentially lead to disturbed function and metabolism in other systems, including the cardiovascular system. Even relatively mild kidney damage can raise blood pressure, mediated by salt and water retention (and hence intravascular volume expansion), sympathetic overactivity, activation of the renin angiotensin aldosterone system and accumulation of endogenous vasopressors. Prospective epidemiologic studies have indicated that there is a log-linear association between higher blood pressure and an increased risk for coronary artery disease, ischemic and hemorrhagic stroke, and congestive heart failure. The Prospective Studies Collaboration showed in a meta-analysis of 61 prospective studies (which included a total of 1,000,000 adults without prior cardiovascular disease with roughly 56,000 cardiovascular deaths) that a prolonged 20 mm Hg increment in usual systolic blood pressure was associated with a more than twofold higher risk for stroke-related death, and a twofold higher risk for death due to coronary artery disease and of death due to heart failure. These relative risks may be substantially larger in younger individuals (in whom the association between blood pressure and cardiovascular death is stronger than in older individuals). Direct risk factors are those that arise as a direct consequence of kidney damage and are associated with one or more types of cardiovascular disease. Large-scale observational studies support inverse association with coronary disease. Relative risk estimated from observational studies (where available) of association between long-term exposure to risk factor and outcome. Estimates for congestive heart failure based on data for coronary artery disease if specific data not available. It is also possible that elevated Lp(a) level might contribute to an increase in risk. The effects of chronic anemia on the cardiovascular system are not well studied in the general population because anemia is generally associated with disease. The results of randomized trials of treatments to increase hemoglobin concentration that involved assessment of cardiovascular end points are discussed later in the "Correction of Anemia" section. They are not attributable to reduced clearance, because renal homocysteine excretion accounts for less than 1% of its elimination, so they must instead involve metabolic disturbances in remethylation and transsulfuration pathways. Phosphate associated with increased vascular stiffness153,154 and calcification,155,156 perhaps because hyperphosphatemia can induce vascular smooth muscle cells to develop an osteoblastic phenotype. The issue is complicated by the possibility of adverse effects of calciumcontaining phosphate binders, which may contribute to vascular calcification by inducing a positive calcium balance, which results in deposition of calcium in the vasculature rather than bone. Some studies have suggested that vitamin D deficiency predisposes patients to diabetes mellitus and raises blood pressure, but again these data are not conclusive. Parathyroid Hormone antioxidant vitamins (vitamins A [-carotene], C, and E) are inversely related to cardiovascular disease incidence and mortality,181 but randomized trials of antioxidant treatments indicate that, at least in the doses studied, use of these drugs does not reduce the risk for cardiovascular disease. The overall prevalence is increasing-driven in part by a rise in the prevalence of obesity and an aging population-and it has been estimated that there will be over 300 million persons globally with type 2 diabetes by 2025. These estimates were not significantly affected by adjustment for traditional cardiovascular risk factors. Oxidative stress leads to a reduction in nitric oxide bioavailability and thus to endothelial dysfunction178 and may also contribute to left ventricular remodeling and fibrosis, and oxidation of lipoproteins. For example, left ventricular mass predicts mortality in patients undergoing dialysis,67,212-214 and the presence of systolic dysfunction can provide further information. The purpose of risk prediction is to identify a high-risk group of patients who will benefit most from interventions. It is important to note that treatment decisions should not be based solely on the risk factor that will be modified by the treatment in question. Treatment decisions based on single risk factors would lead to the undertreatment of the highest-risk patients. The Irbesartan Diabetic Nephropathy Trial compared the effects of irbesartan 300 mg daily, amlodipine 10 mg daily, and placebo among 1715 subjects with type 2 diabetes mellitus and serum creatinine level 1. Irbesartan was shown to be effective at preventing the composite kidney outcome of doubling of serum creatinine level, dialysis, or death. Therefore, the uncertainty surrounding the optimal target should not distract nephrologists from making efforts to reduce blood pressure in patients (especially the very large number of patients with systolic blood pressures well above 140 mm Hg) who frequently are undertreated and therefore left at unnecessary risk. Among persons without established kidney disease, post hoc analyses of randomized trials conducted in the general population have shown that the proportional reduction in the risk for a myocardial infarction or coronary artery disease death, stroke, or coronary revascularization is independent of kidney function. Allocation to ezetimibe/simvastatin was not associated with a significant excess risk for myopathy, hepatitis, or gallstones, and there were no significant excesses of any type of cancer, death from cancer, or death from other noncardiovascular causes. Guidelines have emphasized the importance of treating overall risk rather than individual risk factors. The first three of these studies investigated the effect of two different erythropoietin regimens, normalization of hemoglobin level versus partial correction, on cardiovascular outcomes. The first study randomized 1233 patients undergoing hemodialysis with clinical features suggestive of ischemic heart disease or heart failure. The trial was stopped early (after a median follow-up of 14 months) predominantly because of an excess risk for vascular access thrombosis with higher hemoglobin concentrations. At this point, 33% of patients had died or experienced a nonfatal myocardial infarction in the group randomized to a hemoglobin target of 14. The trial was terminated because patients randomized to achieve a hemoglobin level of 13. However, there have been no placebo-controlled trials investigating the benefits of lowering phosphate level. Current therapies only reduce serum phosphate modestly, although the effects on phosphate balance (as indicated by changes in urinary phosphate excretion) may be larger than suggested by serum phosphate concentration alone. However, a randomized trial comparing sevelamer, lanthanum, and calcium-based phosphate binders found that, overall. The treatment effect was similar on all components of the primary outcome and on both vascular and nonvascular mortality. Although derived from post hoc analysis, these data support the hypothesis that mineral bone disease disturbances contribute to nonatherosclerotic cardiovascular disease. Overall, antiplatelet therapy yielded a 41% proportional reduction in the risk for nonfatal myocardial infarction, nonfatal stroke, or vascular death, which was consistent with the proportional benefit observed among other high-risk patients studied, but there were insufficient data on bleeding risk to assess safety. Blood Pressure Lowering Treatment Trialists Collaboration, Ninomiya T, Perkovic V, et al: Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. Baigent C, Blackwell L, Collins R, et al: Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. For many of the risk factors considered in this chapter, whether they are established as causal. Tonelli M, Wiebe N, Culleton B, et al: Chronic kidney disease and mortality risk: a systematic review. Bright R: Reports of medical cases, selected with a view of illustrating the symptoms and cure of diseases by a reference to morbid anatomy, London, 1827-1831, Longmans. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Taniwaki H, Kawagishi T, Emoto M, et al: Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes. Kawagishi T, Nishizawa Y, Konishi T, et al: High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Briet M, Bozec E, Laurent S, et al: Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Nishizawa Y, Shoji T, Maekawa K, et al: Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Covic A, Mardare N, Gusbeth-Tatomir P, et al: Arterial wave reflections and mortality in haemodialysis patients-only relevant in elderly, cardiovascularly compromised Shoji T, Maekawa K, Emoto M, et al: Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. Ravani P, Tripepi G, Malberti F, et al: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. Amann K: Media calcification and intima calcification are distinct entities in chronic kidney disease. Braun J, Oldendorf M, Moshage W, et al: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Rattazzi M, Bertacco E, Del Vecchio A, et al: Aortic valve calcification in chronic kidney disease. Bruch C, Rothenburger M, Gotzmann M, et al: Chronic kidney disease in patients with chronic heart failure-impact on intracardiac conduction, diastolic function and prognosis. Tamura K, Tsuji H, Nishiue T, et al: Determinants of heart rate variability in chronic hemodialysis patients. Lewington S, Whitlock G, Clarke R, et al: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Kjekshus J, Apetrei E, Barrios V, et al: Rosuvastatin in older patients with systolic heart failure. Essig M, Escoubet B, de Zuttere D, et al: Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease. Leskinen Y, Paana T, Saha H, et al: Valvular calcification and its relationship to atherosclerosis in chronic kidney disease. Amann K, Breitbach M, Ritz E, et al: Myocyte/capillary mismatch in the heart of uremic patients. Di Angelantonio E, Chowdhury R, Sarwar N, et al: Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al: Albuminuria reflects widespread vascular damage. Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Turnbull F, Neal B, Pfeffer M, et al: Blood pressure-dependent and independent effects of agents that inhibit the reninangiotensin system. Speer T, Zewinger S, Fliser D: Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Kronenberg F, Konig P, Lhotta K, et al: Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Di Angelantonio E, Sarwar N, Perry P, et al: Major lipids, apolipoproteins, and risk of vascular disease. Shoji T, Nishizawa Y, Nishitani H, et al: Impaired metabolism of high density lipoprotein in uremic patients. Amarenco P, Labreuche J, Touboul P-J: High-density lipoproteincholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Irish A: Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Tomura S, Nakamura Y, Deguchi F, et al: Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Portoles J, Torralbo A, Martin P, et al: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Tomson J, Emberson J, Hill M, et al: Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths. Rashid G, Bernheim J, Green J, et al: Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Nanasato M, Goto N, Isobe S, et al: Restored cardiac conditions and left ventricular function after parathyroidectomy in a hemodialysis patient. Schulz E, Jansen T, Wenzel P, et al: Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Jha P, Flather M, Lonn E, et al: the antioxidant vitamins and cardiovascular disease. Arnadottir M, Hultberg B, Nilsson-Ehle P, et al: the effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Danesh J, Lewington S: Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. Clarke R, Halsey J, Lewington S, et al: Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Jardine M, Kang A, Zoungas S, et al: the effect of folic acid-based homocysteine lowering on cardiovascular events in people with kidney disease: a systematic review and meta-analysis. Tonelli M, Sacks F, Pfeffer M, et al: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Isakova T, Xie H, Yang W, et al: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Danesh J, Collins R, Peto R, et al: Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Patel A, MacMahon S, Chalmers J, et al: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Wei M quit smoking 4th week order nicotinell pills in toronto, Esbaei K quit smoking meds cheap nicotinell 35 mg on-line, Bargman J quit smoking aids that really work purchase discount nicotinell online, et al: Relationship between serum magnesium quit smoking 26 months ago purchase generic nicotinell pills, parathyroid hormone quit smoking message board buy nicotinell 35 mg with visa, and vascular calcification in patients on dialysis: a literature review quit smoking 2 12 years buy discount nicotinell on-line. Tonelli M, Wiebe N, Culleton B, et al: Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Losito A, Kalidas K, Santoni S, et al: Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Perez Fontan M, Rodriguez-Carmona A, Garcia-Naveiro R, et al: Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Mehrotra R, Singh H: Peritoneal dialysis-associated peritonitis with simultaneous exit-site infection. Bernardini J, Bender F, Florio T, et al: Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. McCormack K, Rabindranath K, Kilonzo M, et al: Systematic review of the effectiveness of preventing and treating Staphylococcus aureus carriage in reducing peritoneal catheter-related infections. Pennell P, Rojas C, Asif A, et al: Managing metabolic complications of peritoneal dialysis. Dong J, Luo S, Xu R, et al: Clinical characteristics and outcomes of "silent" and "non-silent" peritonitis in patients on peritoneal dialysis. Perez-Fontan M, Lueiro F: Escherichia coli peritonitis in patients undergoing peritoneal dialysis: a serious problem that may get worse. Abraham G, Mathews M, Sekar L, et al: Tuberculous peritonitis in a cohort of continuous ambulatory peritoneal dialysis patients. Waness A, Al Shohaib S: Tuberculous peritonitis associated with peritoneal dialysis. Krishnan M, Thodis E, Ikonomopoulos D, et al: Predictors of outcome following bacterial peritonitis in peritoneal dialysis. Van Biesen W, Veys N, Vanholder R, et al: Peritoneal-dialysisrelated peritonitis: the art of rope-dancing. Cozzolino M, Gallieni M, Chiarelli G, et al: Calcium and phosphate handling in peritoneal dialysis. Ramos R, Moreso F, Borras M, et al: Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study. Korzets A, Korzets Z, Peer G, et al: Sclerosing peritonitis: possible early diagnosis by computerized tomography of the abdomen. Kawaguchi Y, Saito A, Kawanishi H, et al: Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Kawanishi H: Surgical and medical treatments of encapsulation peritoneal sclerosis. Kawanishi H, Watanabe H, Moriishi M, et al: Successful surgical management of encapsulating peritoneal sclerosis. Guest S: Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Yeates K, Zhu N, Vonesh E, et al: Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Mehrotra R: Comparing outcomes of hemodialysis and peritoneal dialysis patients: consider the pitfalls. Mircescu G, Stefan G, Garneata L, et al: Outcomes of dialytic modalities in a large incident registry cohort from Eastern Europe: the Romanian Renal Registry. Arrieta J, Rodriguez-Carmona A, Remon C, et al: Peritoneal dialysis is the best cost-effective alternative for maintaining dialysis treatment. Sennfalt K, Magnusson M, Carlsson P: Comparison of hemodialysis and peritoneal dialysis: a cost-utility analysis. Vanholder R, Davenport A, Hannedouche T, et al: Reimbursement of dialysis: a comparison of seven countries. Centers for Medicare and Medicaid Services: Medicare program; end-stage renal disease prospective payment system; final rule and proposed rule. Perl J, Wald R, McFarlane P, et al: Hemodialysis vascular access modifies the association between dialysis modality and survival. Mehrotra R, Kermah D, Fried L, et al: Chronic peritoneal dialysis in the United States: declining utilization despite improving outcomes. Nakamoto H, Kawaguchi Y, Suzuki H: Is technique survival on peritoneal dialysis better in Japan In some cases, the management of the underlying disease itself has important renal implications. The reader is referred to Chapters 15 and 16 for further discussion of these disorders. With regard to inflammatory mediators in sepsis, there has been significant interest in the use of high-volume hemofiltration to remove proinflammatory cytokines, but studies to date have not shown any benefit. However, results of a clinical trial suggested no benefit of early goal-directed therapy, which included early recognition of sepsis and timely antibiotic administration, over standard therapy. There was no difference in 60-day, 90-day, or 1-year mortality between the treatment arms (60-day mortality 21% in the protocolbased early goal-directed therapy arm, 18. Patients in the protocol-based standard therapy and usual care arm received fewer packed red blood cell transfusions and less dobutamine than patients in the other two arms, suggesting that these interventions are of limited benefit in a general population with sepsis. Fluid overload is associated with a number of adverse consequences, including decreased gastrointestinal absorption and impaired wound healing. This pressure is typically measured by instilling a fixed volume of water (30 mL) into the urinary bladder via Foley catheter and using pressure tubing to transduce a bladder pressure from the Foley catheter tubing. The abdominal compartment syndrome is defined as an intra-abdominal pressure greater than 20 mm Hg and the presence of end-organ dysfunction. The main mechanism of renal dysfunction is thought to be compression of the inferior vena cava, which results in impaired venous return and venous stasis throughout the abdominal cavity, including the renal veins. The result is a functional prerenal state, characterized by low urinary sodium concentration and oliguria. Decompression of the abdominal compartment (typically via a surgical approach) may be required, and newer guidelines suggest that consideration should be given to decompression in patients with intraabdominal hypertension before the abdominal compartment syndrome develops. In addition to the amount of fluid, there is significant interest in the type of fluid administered and its impact on renal function. It has been suggested that chloride-rich solutions may be associated with greater renal vasoconstriction and exacerbation of medullary hypoxia. During the intervention period that followed, patients received Plasmalyte or chloride-restricted colloids for resuscitation. In the setting of normal renal function, compensatory metabolic alkalosis will ensue. Studies in animal models suggest there is significant crosstalk between the kidney and the lung-that is, injury to one organ results in injury to the other. Acute tubular necrosis may be caused by hypotension, sepsis (a common complication of acute liver failure), or ingestion of a substance that is both hepatotoxic and nephrotoxic (for example, acetaminophen, Amanita mushrooms). Hyponatremia is a common complication of liver failure and may further exacerbate cerebral edema. There has been significant interest in the optimal management of volume overload in the context of acute decompensated heart failure. Several studies have compared the use of continuous versus intermittent bolus dosing of loop diuretics,43,44 on the basis of the hypothesis that continuous infusion results in more effective diuresis by avoiding periods of "rebound" sodium retention between bolus doses. However, no clear benefit to continuous infusions over bolus dosing has been demonstrated to date. Extracorporeal ultrafiltration has been proposed as an alternative to diuretic management for volume overload in acute decompensated heart failure and has been tested in a number of randomized clinical trials. The trial was terminated early owing to a lack of benefit in the ultrafiltration group (serum creatinine increased slightly in comparison with a slight decrease in the pharmacologic group, and change in weight was the same in the two groups), combined with an increased risk of adverse events, including bleeding and catheter-related complications. On the basis of this experience, ultrafiltration is no longer favored as a first-line therapy for patients with acute decompensated heart failure and cardiorenal syndrome. Changesfrombaselinein(A)serumcreatinineand(B)body weight at various time points, according to treatment group. Furthermore, there may be centerto-center variation in the application of each modality, although practice guidelines now established may stimulate more standardized care. Due to the lower blood flow rates typically achieved with temporary dialysis catheters and the high catabolic rates of critically ill patients, session durations up to 5 hours may be required. Blood flow ranges from 200 to 400 mL/min, with lower blood flows used in initial sessions for patients who are believed to be at risk for dialysis disequilibrium. Critically ill patients may have an array of risks for hypoglycemia, thereby mandating the uniform inclusion of dextrose in the dialysate. In addition to modification of the dialysate sodium concentration, intradialytic hypotension can be prevented by lowering the dialysate temperature or initiating or escalating the doses vasopressors. As an example, one may consider a net ultrafiltration goal of 50 mL/hour being prescribed to an anuric patient. If the patient received 30 mL from parenteral nutrition and 40 mL from a variety infusions and lost 30 mL from a variety of postoperative drains (net balance + 40 mL), the actual ultrafiltration volume needs to be 90 mL. However, inferences from these results are limited by the small sample size and limited statistical power of this trial. The relative contributions of diffusive clearance and convective clearance to the administered therapy may vary and ultimately define the clearance mode (hemodialysis, hemofiltration, or hemodiafiltration). In hemodialysis, a concentration gradient is generated by the countercurrent flow of dialysate and blood across a semipermeable membrane. However, solutes may also be removed as a consequence of convective clearance, whereby the ultrafiltration of large volumes of plasma water down a pressure gradient forces concomitant "drag" of solutes across the membrane pores. In hemofiltration, a balanced electrolyte solution devoid of the unwanted solutes then replaces the ultrafiltrate in an isovolemic fashion. Hemodialysis and hemofiltration are equally effective in the removal of low-molecular-weight substances. However, because diffusion is size-related, slower-moving, larger molecules are less efficiently cleared by dialysis. Depending on the porosity of the membrane, larger molecules, which include potentially toxic cytokines, might be better removed by hemofiltration than by hemodialysis. Hemofiltration may be provided in tandem with hemodialysis (hemodiafiltration) or as the exclusive mode of clearance. No specific advantage of intensive therapy was observed in either study with respect to pre-specified patient subgroups such as those with sepsis. The risk of clotting may be mitigated by administering a continuous saline infusion that is added to blood entering the dialyzer, thereby lowering intradialyzer blood viscosity. Although the relationship between fluid overload and death is likely confounded by a host of factors, an effective ultrafiltration strategy may have many benefits, including reduction in pulmonary edema (which may facilitate ventilator weaning) and mitigation of peripheral edema (which might help the mobilization process). Standard physical examination maneuvers (assessment of the jugular venous pressure, chest auscultation, peripheral edema) may be difficult to apply in the critical care setting and may be complemented by a search for pulmonary congestion on chest radiograph or information gleaned from a transduced central venous pressure. However, given the limitations of all these tools,89,90 emerging technologies such as bedside point-of-care ultrasonography (for assessment of lung fluid91 and inferior vena cava diameter92,93) and bioelectric impedance analysis94 may prove to be useful adjuncts to standard volume assessment techniques. Such hypotension occurs, even in patients with bona fide extracellular volume expansion, through inadequate refilling of the intravascular space from the interstitium to compensate for fluid that was removed. The proclivity for hypotension is further enhanced by impairment of vascular tone, which may result from the underlying illness, medications, or dialysis-induced rise in core body temperature. For patients receiving intermittent modalities, modifications to the dialysate prescription as described previously might mitigate iatrogenic hypotension. In patients with heparin-induced thrombocytopenia, systemically infused argatroban is an appropriate alternative. Systemic calcium level is maintained in the normal range through a concurrent calcium infusion. In the setting of impaired hepatic function, citrate accumulation may occur, theoretically manifesting as a wide anion gap metabolic acidosis and hypocalcemia. An internal jugular catheter tip should be at the atriocaval junction, thereby requiring a catheter length of 15 to 20 cm; a catheter placed in the femoral veins must reach the inferior vena cava and so have an optimal length of at least 20 to 25 cm. Though subclavian catheters may be associated with a lower rate of infection,101 they are generally avoided, owing to the associated higher rate of central vein stenosis, which might preclude the future creation of a permanent vascular access in the ipsilateral arm among individuals who will require permanent dialysis. A randomized clinical trial showed similar rates of catheter colonization among those receiving internal jugular and femoral catheters overall, and no difference in catheter associated-bacteremia. Volume overload may markedly inflate the volume of distribution, necessitating higher loading doses. Once a drug is in the bloodstream, its concentration may be altered by fluctuations in hepatic and renal metabolism. Thus, although published recommendations can be used as a starting point for drug dosing, careful monitoring, by following drug levels when available or by clinical assessment for evidence of toxicity, is warranted. With the current predominant use of high-flux filters, which enhance drug clearance, dosing recommendations that were derived for use with low-flux filters typically need to be increased by 25% to 50%. Bellomo R, Ronco C, Kellum J, et al for the Acute Dialysis Quality Initiative Workgroup: Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs. For a more detailed discussion of this topic, the reader is referred to Chapter 64. Wilson P, Lertdumrongluk P, Leray-Moragues H, et al: Prevention and management of dialysis catheter complications in the intensive care unit. The Second International Consensus Conference of the Acute Dialysis Quality Initiative Group. I: acute renal failure in critically ill patients: a multinational, multicenter study. Gomez H, Ince C, De Backer D, et al: A unified theory of sepsisinduced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury.

Zaza G quit smoking year 2 generic nicotinell 35 mg amex, Granata S quit smoking 2 years ago still anxiety purchase nicotinell amex, Sallustio F quit smoking 8 years order genuine nicotinell online, et al: Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients quit smoking on your own buy nicotinell 52.5mg with amex. Chatenoud L quit smoking florida free patches purchase nicotinell mastercard, Dugas B quit smoking 8 years cheap 35mg nicotinell free shipping, Beaurain G, et al: Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. Thus, alterations in signal-feedback mechanisms and in production, transport, metabolism, elimination, and protein binding of hormones occur rather commonly in conditions affecting the kidney. The purpose of this chapter is to overview specific endocrine abnormalities that manifest as a consequence of kidney disease. If there is a concomitant inadequate secretion of insulin, this condition is manifested as abnormal glucose tolerance and if severe as diabetes mellitus. Indeed, treatment of hyperparathyroidism2 and pharmacologic doses of vitamin D3 have been reported to correct glucose tolerance. Later evidence suggests that fructose not only induces metabolic syndrome, hyperuricemia, and weight gain15 but also exerts direct adverse effects on renal tubular cells. Animal models of insulin deficiency suggest that the effect of insulin on protein turnover is mediated through the activation of the ubiquitin proteasome pathway. In a later evaluation of new users of oral hypoglycemic medication monotherapy in patients with type 2 diabetes mellitus, higher risk of mortality was associated with glibenclamide, glipizide, and rosiglitazone than with metformin. A cross-sectional evaluation showed significantly higher (>38%) cardiovascular and all-cause mortality in rosiglitazone users,51 consistent with a systematic review of trials in patients with type 2 diabetes mellitus that showed increased risk of myocardial infarction and a borderline increased risk of death from cardiovascular causes. Thus, a decline of kidney function is accompanied by a characteristic disturbance in thyroid physiology Table 58. Medications that are able to suppress thyroid hormone metabolism include corticosteroids, amiodarone, propranolol, and lithium. Free and total thyroxine (T4) concentrations may be normal or slightly reduced, mainly as a result of impaired hormone binding to serum carrier proteins. For example, urea, creatinine, indoles, and phenols all strongly inhibit protein binding of T4. Such finding differentiates the uremic patient from patients with other chronic illnesses. In addition, bioavailability and cell uptake of thyroid hormones may be partially blunted in uremia, leading to a state of thyroid resistance. In normal rat hepatocytes, treatment with serum from uremic patients reduced T4 uptake by 30%. In patients younger than 3 years, the head circumference should be routinely monitored as well. As a growth factor, prolactin influences hematopoiesis, angiogenesis, and blood clotting. Prolactin modulates the inflammatory response, stimulates the adhesion of mononuclear cells to endothelium, and enhances vascular smooth muscle cell proliferation. Whether these effects were, at least partly, mediated by prolactin reduction is unknown. Although bromocriptine treatment has proved to decrease prolactin levels in uremic men and women,126 the previously mentioned symptoms do not fully disappear, suggesting that other factors may contribute in parallel. It is possible that prolactinemia may have previously underrecognized effects independent of its effects on the gonads. Aldosterone increases oxidative stress and promotes vascular inflammation143,144 and impairs vascular reactivity by limiting the bioavailability of nitric oxide. Ovarian dysfunction in women undergoing dialysis is characterized by the absence of cyclic gonadotropin and estradiol release, which results in the lack of progestational changes in the endometrium. However, it seems that the endometrium has preserved normal reactivity to circulating estrogens. Hypogonadism in women has been linked with sleep disorders, depression, urinary incontinence, and, in the long term, with osteoporosis, impaired cognitive function, and increased cardiovascular risk. Changes in lifestyle, such as smoking cessation, strength training, and aerobic exercises, may decrease depression, enhance body image, and have positive effects on sexuality. Sexual dysfunction in these patients should be thought of as a multifactorial problem that is affected by a variety of physiologic and psychological factors as well as comorbid conditions. In addition to a number of endocrine alterations described later, diabetes and vascular disease, for instance, can interfere with the ability of the male patient to achieve an erection and the female patient to achieve sexual arousal. Various psychological factors, such as depression, can significantly and adversely affect sexual function in both sexes. Chronic anovulation and lack of progesterone secretion in uremic women may be treated with oral progesterone. Low estradiol levels in amenorrheic women undergoing dialysis can lead to vaginal atrophy and dyspareunia; topical estrogen cream and vaginal lubricants may be helpful in these patients. Uremic women who are menstruating normally should be encouraged to use birth control. Estradiol hormonal replacement therapy was able to restore regular menses and improve sexual function in premenopausal estrogen-deficient women undergoing dialysis168 and to improve bone histomorphometry in animal models of uremia. In experimental animal models, endogenous estrogens have shown antifibrotic and anti-apoptotic effects in the kidney,175,176 and exogenous estradiol in ovariectomized rats attenuated glomerulosclerosis and tubulointerstitial fibrosis177 by protecting podocytes against injury through upregulation of estrogen receptor. However, clinical evidence in this regard is elusive, with evidence suggesting that both estrogen replacement therapy and oral contraceptives are associated with albuminuria, increased creatinine clearance, and loss of kidney function. A well-functioning kidney transplant is likely to restore normal sexual activity, although some features of reproductive function may remain impaired. Semen analysis typically shows a decreased volume of ejaculate, either low sperm count or complete azoospermia, and a low percentage of motility. Other drugs, such as spironolactone, ketoconazole, glucocorticoids, and cimetidine, can interfere directly with the synthesis of sex hormones. Reduced testosterone levels in male patients undergoing hemodialysis have been linked to increased mortality risk, especially that from cardiovascular causes. In physiologic conditions, testosterone is an anabolic hormone that plays an important role in inducing skeletal muscle hypertrophy by promoting nitrogen retention, stimulating fractional muscle protein synthesis, inducing myoblast differentiation, and augmenting the efficiency of amino acid reuse by the skeletal muscle. However, testosterone may also have direct atheroprotective effects in the cardiovascular system. Thus, low testosterone could be considered a biomarker of chronic inflammatory disease. Alternative modes of administration, such as intramuscular injection, may ease compliance and bioavailability. Because psychosocial factors may also take part in the pathophysiology of erectile dysfunction, nocturnal penile tumescence testing may be used to differentiate organic and psychological causes of impotence. In line with this thinking, a population-based study of men reported that impaired kidney function and low serum testosterone concentrations were additive (and independent) mortality risk factors. A large case-control study involving more than 10,000 men newly diagnosed with nonmetastatic prostate cancer demonstrated that androgen deprivation therapy increased the risk of acute kidney injury. An additional explanation for the role of hypogonadism on kidney injury was demonstrated in male rats subjected to renal ischemia followed by reperfusion. These prohormones are obtained mainly from sun exposure (by photochemical conversion of 7-dehydrocholesterol in the skin), food (especially fatty fish), and nutritional supplements. These prohormones are converted by hydroxylation in the liver to 25-hydroxyvitamin D, and by a second hydroxylation step (performed by the 1-hydroxylase) to its active form, 1,25-dihydroxyvitamin D (calcitriol). Extrarenal calcitriol is converted in other tissues, including the skin, colon, prostate, and macrophages, but the regulatory processes for this conversion are not well understood. Calcitriol has a half-life of only 4 to 6 hours, and the circulating levels are low. Calcitriol also promotes bone mineralization, bone growth, and bone remodeling by osteoblasts and osteoclasts, and prevents hypocalcemia. Vitamin D deficiency has been linked to multiple disorders, including growth retardation, skeletal abnormalities (osteopenia, osteoporosis, and increased risk of fractures), muscle weakness, left ventricular hypertrophy, as well as increased susceptibility to cancer, diabetes, and autoimmune and infectious diseases. It stimulates excretion of phosphate by the renal tubular cells and indirectly modulates intestinal calcium absorption by stimulating the activation of calcitriol synthesis. As vitamin D deficiency progresses, the parathyroid glands are maximally stimulated, causing secondary hyperparathyroidism. Hyperparathyroidism has been implicated in left ventricular hypertrophy as well as in the metabolic syndrome contributing to impaired glucose tolerance and dyslipidemia. Unless a person eats oily fish frequently, it is difficult to provide that much vitamin D3 on a daily basis from dietary sources. Shinohara K, Shoji T, Emoto M, et al: Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. Zoccali C, Mallamaci F, Tripepi G, et al: Low triiodothyronine and survival in end-stage renal disease. Garibotto G, Russo R, Sofia A, et al: Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases. Guebre-Egziabher F, Juillard L, Boirie Y, et al: Short-term administration of a combination of recombinant growth hormone and insulin-like growth factor-I induces anabolism in maintenance hemodialysis. Ravani P, Malberti F, Tripepi G, et al: Vitamin D levels and patient outcome in chronic kidney disease. Marette A: Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Lofgren P, van Harmelen V, Reynisdottir S, et al: Secretion of tumor necrosis factor-alpha shows a strong relationship to insulinstimulated glucose transport in human adipose tissue. Rieusset J, Bouzakri K, Chevillotte E, et al: Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Abe M, Okada K, Soma M, et al: Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients. Allegra V, Mengozzi G, Martimbianco L, et al: Glucose-induced insulin secretion in uremia: effects of aminophylline infusion and glucose loads. Furuya R, Odamaki M, Kumagai H, et al: Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Kobayashi H, Tokudome G, Hara Y, et al: Insulin resistance is a risk factor for the progression of chronic kidney disease. Stenvinkel P, Ottosson-Seeberger A, Alvestrand A: Renal hemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidemia. Olesen P, Nguyen K, Wogensen L, et al: Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Mustata S, Chan C, Lai V, et al: Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. Montenegro J, Gonzalez O, Saracho R, et al: Changes in renal function in primary hypothyroidism. Enia G, Panuccio V, Cutrupi S, et al: Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Zoccali C, Benedetto F, Mallamaci F, et al: Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. Tatar E, Kircelli F, Asci G, et al: Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Tatar E, Sezis Demirci M, Kircelli F, et al: the association between thyroid hormones and arterial stiffness in peritoneal dialysis patients. Feldt-Rasmussen B, El Nahas M: Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease. Sato K, Okamura K, Yoshinari M, et al: Reversible primary hypothyroidism and elevated serum iodine level in patients with renal dysfunction. Vanhorebeek I, Langouche L, Van den Berghe G: Endocrine aspects of acute and prolonged critical illness. Disthabanchong S, Treeruttanawanich A: Oral sodium bicarbonate improves thyroid function in predialysis chronic kidney disease. Chonchol M, Lippi G, Salvagno G, et al: Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Wuhl E, Schaefer F: Effects of growth hormone in patients with chronic renal failure: experience in children and adults. Haffner D, Schaefer F, Nissel R, et al: Effect of growth hormone treatment on the adult height of children with chronic renal failure: German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Hokken-Koelega A, Mulder P, De Jong R, et al: Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Feldt-Rasmussen B, Lange M, Sulowicz W, et al: Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. Guebre-Egziabher F, Juillard L, Boirie Y, et al: Shortterm administration of a combination of recombinant growth hormone and insulin-like growth factor-I induces anabolism in maintenance hemodialysis. Feld S, Hirschberg R: Growth hormone, the insulin-like growth factor system, and the kidney. Yavuz D, Topcu G, Ozener C, et al: Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy. Bommer J, Ritz E, del Pozo E, et al: Improved sexual function in male haemodialysis patients on bromocriptine. Mejia-Rodriguez O, Alvarez-Aguilar C, Ledesma-Ramirez M, et al: Therapeutic effect of bromocriptine together with the established treatment for hypertension in patients undergoing peritoneal dialysis. Degli Esposti E, Sturani A, Santoro A, et al: Effect of bromocriptine treatment on prolactin, noradrenaline and blood pressure in hypertensive haemodialysis patients. Si J, Ge Y, Zhuang S, et al: Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Stehman-Breen C, Anderson G, Gibson D, et al: Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, et al: the benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Hernandez E, Valera R, Alonzo E, et al: Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Simon J, Braunstein G, Nachtigall L, et al: Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. Maric C, Sandberg K, Hinojosa-Laborde C: Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat.

Cheap nicotinell 52.5mg online. MUST WATCH! FREE Stop Smoking Hypnosis Session.

Diseases

• Cold antibody hemolytic anemia
• Sharma Kapoor Ramji syndrome
• Dubowitz syndrome
• Hypergeusia
• Enolase deficiency type 2
• Hypodontia of incisors and premolars